GIC invests HK$659m in Bloomage in bet on Botox
Singapore
GIC Pte's private-equity unit has invested HK$659 million (S$119 million) in Hong-Kong listed Bloomage BioTechnology Corporation Ltd, as it taps into China's growing medical cosmetics market.
The investment consists of HK$465 million convertible bonds and HK$194 million new shares at a subscription price of HK$12 each, Singapore's GIC and Bloomage said in a joint statement on Thursday. Bloomage shares surged 8.2 per cent to HK$15 in Hong Kong at 2:55pm.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Apple is working on its own AI chip for data centres: WSJ
European oil giants consider shifting their listings to the US
ExxonMobil sees Hess arbitration dragging into 2025, CEO says
Gold prices tick higher on US rate cut bets
Nomura targets 20% revenue growth from global markets business